ALLMedicine™ Multiple Sclerosis Center
Research & Reviews 17,972 results
https://doi.org/10.1007/978-3-030-56153-6_3 10.1101/cshperspect.a028936 10.1186/s12974-017-1049-5 10.2353/ajpath.2008.070690 10.4049/jimmunol.169.9.4712 10.1146/annurev.immunol.23.021704.115707 10.1001/archneur.58.12.1975 10.1046/j.1365-2990.2000.026002133.x 10.1016/S0165-5728(02)00097-8 10.1101/cshperspect.a029025 10.1038/nri2548 10.1038/nrd1752 10.1111/j.1365-2990.2004.00638.x 10.1038/ni1415 10.3389/fimmu.2017.00321 10.1212/WNL.53.3.466 10.1002/glia.1111 10.1186/1476-4598-12-86 10.1093/intimm/dxv025 10.1016/j.it.2004.03.008 10.1172/JCI11916 10.1186/1476-9433-3-1 10.1371/journal.pone.0092325 10.1136/rmdopen-2015-000061 10.1016/S0027-5107(01)00183-X 10.1016/S0166-2236(96)01035-1 10.1093/hmg/11.11.1281 10.1016/S0002-9440(10)65456-9 10.1007/112_2013_11 10.1002/jcp.25778 10.1097/CEJ.0b013e32832c389e 10.1080/10408398.2017.1358139 10.1055/s-0043-100019 10.1111/bph.13621 10.1371/journal.pone.0079084 10.1016/j.biopha.2017.04.070 10.1007/s10875-006-9066-7 10.4049/jimmunol.174.12.8116 10.1515/aoas-2015-0079 10.1186/s12967-018-1381-2 10.1111/cei.12322 10.1016/j.intimp.2016.05.007 10.1186/1742-2094-11-59 10.1242/jcs.00963 10.1371/journal.pone.0040724 10.1158/1078-0432.CCR-10-0446 10.1016/j.intimp.2013.06.020 10.1016/j.archoralbio.2013.07.005 10.1016/j.pharep.2018.05.008 10.1016/j.intimp.2018.05.018 10.1016/j.neuropharm.2015.07.013 10.1016/j.intimp.2009.01.025 10.1007/s10875-008-9202-7 10.1016/j.bcp.2005.04.041 10.4049/jimmunol.168.12.6506 10.1080/13543776.2018.1530217 10.1111/acel.12322 10.1128/IAI.68.12.7010-7017.2000 10.3892/ijmm.2012.1184 10.1016/j.molmed.2007.09.002 10.1007/s11010-008-9949-4 10.1016/S0024-3205(02)01510-2 10.1097/01.CCM.0000221921.71300.BF 10.15407/fz58.02.033 10.1155/2013/470975 10.1186/s13148-015-0110-4 10.4103/ASJO.ASJO_96_16 10.1186/1471-2377-6-12 10.1093/brain/awl170 10.1006/bbrc.1997.7064 10.1093/carcin/bgm248 10.1016/j.intimp.2006.11.006 10.1016/j.tox.2006.07.027 10.1089/08977150151071035 10.1097/00002371-199210000-00004 10.1126/science.274.5288.782 10.2174/138955706777934937 10.1038/sj.onc.1202980 10.1016/j.bbrc.2008.07.068 10.1006/bbrc.2001.5361 10.1038/34184 10.1186/1742-2094-1-3 10.3390/cancers3043894 10.1016/j.hermed.2015.03.001 10.1021/mp700113r
Advances in Experimental Medicine and Biology; Gachpazan M, Habbibirad S et. al.
Aug 1st, 2021 - Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, which involves an auto-immune mechanism that leads to perivascular demyelination. The role of nuclear factor-kappa B (NF-κB) signaling pathway in the pathogen...
https://doi.org/10.1016/j.clineuro.2021.106828
Clinical Neurology and Neurosurgery; Leonardi S, Maggio MG et. al.
Aug 1st, 2021 - Multiple sclerosis (MS) can adversely affect several domains of cognitive function, including attention, information processing, memory and learning, executive functions and visuospatial skills. In recent years, technological innovations have prov...
https://doi.org/10.1016/j.msard.2021.103147
Multiple Sclerosis and Related Disorders; O GG, C AD et. al.
Aug 1st, 2021 - There is scarce epidemiological data on Multiple Sclerosis (MS) in Latin America. National epidemiological studies are needed to guide the health policy related to MS. To determine MS national prevalence in Peru and describe clinical and epidemiol...
https://doi.org/10.1016/j.msard.2021.103162
Multiple Sclerosis and Related Disorders; Wnuk M, Maluchnik M et. al.
Aug 1st, 2021 - The detailed data concerning multiple sclerosis (MS) epidemiology in Poland are based on studies from few and less populated provinces. Therefore, we evaluated MS incidence and prevalence in Poland using electronic administrative health claims (AH...
https://doi.org/10.1016/j.msard.2021.103146
Multiple Sclerosis and Related Disorders; Rimkus CM, Schoeps VA et. al.
Aug 1st, 2021 - Some drugs and medications can precipitate immune system deregulations, which might be confused with recurrent demyelinating diseases, such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMO), exacerbations of an existing ...
Guidelines 15 results
https://doi.org/10.1016/j.apmr.2020.08.003
Archives of Physical Medicine and Rehabilitation; Costa SL, Pandey K et. al.
Sep 29th, 2020 - Vision Problems in Multiple Sclerosis.|2020|Costa SL,Pandey K,Hrdina J,Rondon M,Devos H,|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538221
Neurology Kapoor R, Smith KE et. al.
Jul 18th, 2020 - There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes...
https://doi.org/10.1016/j.apmr.2020.03.009
Archives of Physical Medicine and Rehabilitation; Siengsukon C, Karahan AY et. al.
May 14th, 2020 - Practical Sleep Information for People With Multiple Sclerosis.|2020|Siengsukon C,Karahan AY,Strober L,|
https://doi.org/10.1016/j.msard.2019.04.004
Multiple Sclerosis and Related Disorders; Lebrun C, Vukusic S et. al.
Jun 5th, 2019 - To establish recommendations on immunization for patients with multiple sclerosis (MS) BACKGROUND: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have b...
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.
Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...
Drugs 356 results see all →
Clinicaltrials.gov 839 results
https://clinicaltrials.gov/ct2/show/NCT03355365
May 6th, 2020 - The IT-MSC-NP treatments and all clinical assessments will take place at a single center (Tisch MSRCNY). Study subjects will be assigned to blocks stratified by baseline EDSS score (3.0-4.0, 4.5-5.5, 6.0, and 6.5) and disease subtype (SPMS or PPMS...
https://clinicaltrials.gov/ct2/show/NCT00001248
May 5th, 2020 - Studies performed under 89-N-0045 are primarily designed to examine the natural history of multiple sclerosis (MS) and its mimickers, viewed through the window of imaging (especially magnetic resonance imaging or MRI). The protocol has four other ...
https://clinicaltrials.gov/ct2/show/NCT02545868
May 5th, 2020 - This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine [23-PPV] either unboosted or boosted with 13-valent pneumo...
https://clinicaltrials.gov/ct2/show/NCT03249714
May 4th, 2020 - This study has 2 parts: A controlled Core and an open-label Extension. Core part: A 24-week, randomized, double-blind, placebo controlled, parallel-group, multicenter study to evaluate the efficacy, safety and tolerability and PK of ofatumumab in ...
https://clinicaltrials.gov/ct2/show/NCT03723356
May 4th, 2020 - Multiple sclerosis (MS) is the most common progressive neurologic disorder to occur in adults of working-age. Despite longstanding recognition of cognitive impairment as a symptom of MS, two obstacles in measurement have limited understanding its ...
News 2,605 results
https://www.medscape.com/viewarticle/953988
Jun 30th, 2021 - Patients with multiple sclerosis (MS) may soon have another less expensive, more convenient treatment option compared with other agents in the same drug class, new research suggests. Results from two new phase 3 trials show that the investigationa...
https://www.medscape.com/viewarticle/951589
Jun 14th, 2021 - This transcript has been edited for clarity. Hello. This is Paul Auwaerter for Medscape Infectious Diseases, speaking from Johns Hopkins University School of Medicine. Spring is in full swing and tick season has certainly returned. I thought I wou...
https://www.medscape.com/viewarticle/952062
May 28th, 2021 - The US Food and Drug Administration (FDA) has approved ozanimod (Zeposia) for adults with moderately to severely active ulcerative colitis (UC), the company has announced. Ozanimod (0.92 mg), an oral medication taken once daily, is the first sphin...
https://www.medscape.com/viewarticle/951346
May 19th, 2021 - NEW YORK (Reuters Health) - RNA, DNA, protein, and inactivated COVID-19 vaccines are likely safe for multiple sclerosis (MS) patients but live-attenuated ones should be avoided when possible, researchers say. Dr. Hesham Abboud of Case Western Rese...
https://www.medscape.com/viewarticle/951052
May 13th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Dr Ilya Kister Antibody response is reduced in patients with multiple sclerosis (MS) who take a specific disease-modifying therapy (DMT) while inf...
